Represents the amount of cash and cash equivalent invested in a single money market fund.

No definition available.

Name:	amag_AmountInvestedInSingleMoneyMarketFund
Namespace Prefix:	amag_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Details

Name:	amag_InvestmentConcentrationRiskAbstract
Namespace Prefix:	amag_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The approximate percentage of revenues from customers outside the U.S. to total revenues.

+ References

No definition available.

+ Details

Name:	amag_PercentageOfRevenueFromCustomersOutsideUS
Namespace Prefix:	amag_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	amag_PercentageOfRevenuesFromCustomersOutsideOfUSAbstract
Namespace Prefix:	amag_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name:	us-gaap_CashAndCashEquivalentsAtCarryingValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Details

Name:	us-gaap_ConcentrationRiskLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13537-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6404-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13531-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6351-108592

+ Details

Name:	us-gaap_ConcentrationRiskPercentage1
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Sum of investments and unrestricted cash as of the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.1,2)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

+ Details

Name:	us-gaap_InvestmentsAndCash
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

+ Details

Name:	us-gaap_MoneyMarketFundsAtCarryingValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Details

Name:	us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_MajorCustomersAxis=amag_AmerisourceBergenDrugCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_MajorCustomersAxis=amag_CardinalHealthIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_MajorCustomersAxis=amag_McKessonCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Summary of Significant Accounting Policies (Details 4) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Investment Concentration Risk
Cash, cash equivalents and investments	144,200,000us-gaap_InvestmentsAndCash
Investment in institutional money market funds	77,300,000us-gaap_MoneyMarketFundsAtCarryingValue
Cash and cash equivalents	119,296,000	26,986,000	46,293,000	63,474,000
Amount invested in a single fund	60,300,000
Minimum [Member]
Customers representing 10% or more of revenues
Percentage of revenues from major customer	10.00%
Amerisource Bergen Drug Corporation [Member]
Customers representing 10% or more of revenues
Percentage of revenues from major customer	45.00%	43.00%
McKesson Corporation [Member]
Customers representing 10% or more of revenues
Percentage of revenues from major customer	12.00%	29.00%
Cardinal Health Inc [Member]
Customers representing 10% or more of revenues
Percentage of revenues from major customer		19.00%
Cardinal Health Inc [Member] \| Maximum
Customers representing 10% or more of revenues
Percentage of revenues from major customer	10.00%
Sales Revenue, Net [Member] \| Customer Concentration Risk [Member] \| Amerisource Bergen Drug Corporation [Member]
Customers representing 10% or more of revenues
Percentage of revenues from major customer	34.00%	41.00%	34.00%
Sales Revenue, Net [Member] \| Customer Concentration Risk [Member] \| McKesson Corporation [Member]
Customers representing 10% or more of revenues
Percentage of revenues from major customer	21.00%	24.00%	17.00%
Sales Revenue, Net [Member] \| Customer Concentration Risk [Member] \| Cardinal Health Inc [Member]
Customers representing 10% or more of revenues
Percentage of revenues from major customer	15.00%	16.00%	12.00%
Sales Revenue, Net [Member] \| Customer Concentration Risk [Member] \| Takeda Pharmaceutical Company Limited [Member]
Customers representing 10% or more of revenues
Percentage of revenues from major customer	11.00%	11.00%	31.00%
Sales Revenue, Net [Member] \| Customer Concentration Risk [Member] \| Group Purchasing Organization [Member]
Customers representing 10% or more of revenues
Percentage of revenues from major customer	26.00%	30.00%	32.00%
Sales Revenue, Net [Member] \| Geographic Concentration Risk [Member]
Percentage of revenues From customers outside of the U.S.
Approximate percentage of revenues from customers outside the U.S.	12.00%	11.00%	32.00%